针对癌症治疗的Claudin-18.2:从2024年ASCO年会的更新
Katherine I Zhou1, John H Strickler1,2, Hui Chen3,4
1Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, 27708, Durham, NC, USA.
Journal of hematology & oncology
|August 25, 2024
概括
结合化疗的zolbetuximab显著改善了晚期胃食道腺癌的存活率. 针对克劳丁-18.2 (CLDN18.2) 的新疗法也显示出对各种癌症的前景.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 分子向疗法分子向疗法
背景情况:
- 克劳丁-18异型2 (CLDN18.2) 是治疗晚期胃食道腺癌和其他固体瘤的标.
- 目前正在开发针对CLDN18.2的多种治疗策略.
研究的目的:
- 为介绍第3期SPOTLIGHT试验的最终结果,用于先进的胃食道腺癌的第一线治疗.
- 审查在ASCO2024上提交的关于新型CLDN18.2向剂的早期试验数据.
主要方法:
- 第三期SPOTLIGHT试验评估佐尔贝图西马布加化疗.
- 早期阶段的试验评估了FG-M108,LM-302,IBI343,IBI38和satricabtagene的自身细胞.
主要成果:
- 在CLDN18.2-阳性 (≥75%) 晚期胃食道腺癌患者中,Zolbetuximab在添加到化疗时显示出显著的生存益处.
- 早期的试验显示,FG-M108在结合胃食道和胰腺癌的化疗中具有有希望的疗效和安全性.
- 其他针对CLDN18.2的药物 (ADC,双特异抗体,CAR-T) 正在针对耐火实体瘤进行研究.
结论:
- 在特定的晚期胃食道腺癌的第一线治疗中,zolbetuximab加上化疗提供了生存优势.
- 新兴的CLDN18.2向疗法显示出扩大各种CLDN18.2阳性癌症的治疗选择的潜力,包括那些表达水平较低的癌症.
关键词:
抗体疗法是一种抗体疗法.抗体药物联结物 抗体药物联结物双特异性抗体 双特异性抗体化学抗原受体T细胞治疗克劳丁-18.2 的使用情况胃食道腺癌是胃食道腺癌.胃肠道的癌症 胃肠道的癌症有针对性的治疗方法.更多相关视频
14:14Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
15.8K
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.0K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K